However, given the limited therapeutic benefit of anti-PD-(L)1 antibodies as single agents, it is crucial to identify the immune mechanisms involved in tumour resistance to immune checkpoint blockade (ICB) and develop more effective combinatorial approaches. This evidence concerns the gene CD274 and neoplasm.